| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | NEXILICO, INC. | 98 AMBERFIELD LN | DANVILLE | CA | 94506-1332 | CONTRA COSTA | USA | R41TR003571 | Computational prediction of gut microbiome-mediated drug metabolism | 000 | 1 | NIH | 11/28/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $275,765 ) |
| | 2023 | 2023 | NEXILICO, INC. | 98 AMBERFIELD LN | DANVILLE | CA | 94506-1332 | CONTRA COSTA | USA | R41ES034979 | Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation | 000 | 1 | NIH | 9/1/2023 | $275,765 |
|
| Issue Date FY: 2022 ( Subtotal = $55,000 ) |
| | 2022 | 2022 | NEXILICO, INC. | 98 AMBERFIELD LN | DANVILLE | CA | 94506-1332 | CONTRA COSTA | USA | R41TR003571 | Computational prediction of gut microbiome-mediated drug metabolism | 000 | 1 | NIH | 4/26/2022 | $55,000 |
|
| Issue Date FY: 2021 ( Subtotal = $325,000 ) |
| | 2021 | 2021 | NEXILICO, INC. | 580 OHLONE AVE | ALBANY | CA | 94706-1903 | ALAMEDA | USA | R41TR003571 | Computational prediction of gut microbiome-mediated drug metabolism | 000 | 1 | NIH | 4/14/2021 | $325,000 |
| | 2021 | 2019 | NEXILICO, INC. | 98 AMBERFIELD LN | DANVILLE | CA | 94506-1332 | CONTRA COSTA | USA | R43GM130228 | A Predictive Computational Platform for Gut Microbiome Precision Medicine | 000 | 1 | NIH | 3/12/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $224,929 ) |
| | 2019 | 2019 | NEXILICO, INC. | 580 OHLONE AVE | ALBANY | CA | 94706-1903 | ALAMEDA | USA | R43GM130228 | A Predictive Computational Platform for Gut Microbiome Precision Medicine | 000 | 1 | NIH | 5/2/2019 | $224,929 |
|
|
